BlackJack3DStelara, Johnson & Johnson's (NYSE:JNJ) leading product, is nearing the end of its exclusivity outside the US by mid-2024 and in the US by early 2025. Stelara is a significant part of JNJ's sales and operating income, making up about 13% of total sales and 24% of operating income in 2023. This loss of exclusivity will likely slow down the growth of earnings per share (EPS) for JNJ, which is a shift from their previous aim of growing EPS faster than sales. Analysts currently predict declines o ...

Mario Tama Dear readers, Johnson & Johnson (NYSE:JNJ) is arguably one of the safest businesses in the world, as it is one of only two companies that have an AAA rating which is higher than the AA+ rating of the U.S. government. It is also a dividend king with a 60+ year history of dividend increases and a defensive stock which I believe is suitable for most portfolios. I argued in a recent article on Procter & Gamble (PG) why I like to allocate a portion of my capital to Staples. JNJ shares a lot of the sam ...

yorkfotoIntroduction "What's the Fed going to do?" may be the single most important question this year. If we were to ask the market, it would tell us that the Fed will cut rates six times this year. CME GroupWhile Fed Funds Futures, the tool used to arrive at this estimate, are highly volatile, I believe the fact that six cuts are now the consensus estimate worries me a bit. After all, if inflation remains elevated, the Fed will have to keep rates higher for longer, causing markets to price in the impa ...

Johnson & Johnson (JNJ) closed the most recent trading day at $160.97, moving +0.63% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.8%. Elsewhere, the Dow saw a downswing of 0.76%, while the tech-heavy Nasdaq depreciated by 1.18%.Prior to today's trading, shares of the world's biggest maker of health care products had gained 0.9% over the past month. This has lagged the Medical sector's gain of 5.8% and the S&P 500's gain of 3.4% in that time.The invest ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2024 of $1.19 per share on the company’s common stock. The dividend is payable on March 5, 2024 to shareholders of record at the close of business on February 20, 2024. The ex-dividend date is February 16, 2024. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to ...

A federal judge said Johnson & Johnson shareholders may pursue as a class action their lawsuit accusing the company of fraudulently concealing how its talc products were contaminated by cancer-causing asbestos. U.S. District Judge Zahid Quraishi in Trenton, New Jersey, on Friday allowed shareholders from Feb. 22, 2013, to Dec. 13, 2018, to pursue their securities fraud claims as a group.He rejected J&J's argument that any class period be at least a year shorter because some events that allegedly caused its ...

智通财经APP获悉，强生(JNJ.US)旗下的Janssen Biotech 签署了一项价值高达17亿美元的许可协议，以开发和商业化韩国LegoChem Biosciences公司的候选药物LCB84。 根据该协议，Janssen将预先支付1亿美元，获得开发和商业化Trop2靶向抗体药物偶联物(ADC)LCB84的全球独家权利。LegoChem还有资格获得2亿美元的期权行权付款、各种里程碑付款以及净销售额的分级特许权使用费。 据了解，LCB84最近在美国启动了1/2期研究，用于潜在的癌症治疗。 ...

FatCamera When looking for dividend stocks, I'm as concerned about capital growth as I am about compounding safe income. The issue is that companies that pay dividends (unless required by law) often do so because it's the most efficient use of cash to return value to shareholders. But this often comes at the expense of company growth. But I don't think this entirely holds for Johnson & Johnson (NYSE:JNJ). In addition to paying out excellent dividends, it's also using that excess cash to make a bold leap ...

Worldwide and Regional Sales Performance - Worldwide sales for the fiscal nine months of 2023 were $63.8 billion, a 6.2% increase compared to $60.1 billion in 2022, with operational growth of 7.5% and a negative currency impact of 1.3%[208] - U.S. sales for the fiscal nine months of 2023 were $34.4 billion, a 10.5% increase compared to the prior year, with acquisitions and divestitures contributing a positive 2.5% to operational growth[209] - International sales for the fiscal nine months of 2023 were $29.3 billion, a 1.5% increase, including operational growth of 4.2% and a negative currency impact of 2.7%[209] - Sales in Europe for the fiscal nine months of 2023 declined by 0.6%, with operational decline of 1.0% and a positive currency impact of 0.4%[210] - Worldwide sales for the fiscal third quarter of 2023 were $21.4 billion, a 6.8% increase compared to $20.0 billion in 2022, with operational growth of 6.4% and a positive currency impact of 0.4%[211] - U.S. sales for the fiscal third quarter of 2023 were $12.0 billion, an 11.1% increase compared to the prior year, with acquisitions and divestitures contributing a positive 2.2% to operational growth[212] - International sales for the fiscal third quarter of 2023 were $9.4 billion, a 1.6% increase, including operational growth of 0.7% and a positive currency impact of 0.9%[212] Innovative Medicine Segment Performance - Innovative Medicine segment sales for the fiscal nine months of 2023 were $41.0 billion, a 4.2% increase compared to the same period a year ago, with operational growth of 5.1% and a negative currency impact of 0.9%[214] - U.S. Innovative Medicine sales for the fiscal nine months of 2023 increased by 8.8% compared to the same period a year ago, while international sales decreased by 1.2%[214] - Innovative Medicine segment sales for the fiscal third quarter of 2023 were $13.9 billion, a 5.1% increase compared to the same period a year ago, with operational growth of 4.3% and a positive currency impact of 0.8%[216] - Immunology products achieved operational growth of 12.4%, with STELARA sales reaching $2.864 billion, a 16.9% increase year-over-year[217][219] - Infectious Diseases sales declined by 37.8% operationally, primarily due to a 91.5% drop in COVID-19 vaccine revenue to $41 million[217][220] - Neuroscience products grew 4.6% operationally, driven by SPRAVATO sales increasing 82.1% to $183 million[217][221] - Oncology products saw 10.4% operational growth, with DARZALEX sales up 21.8% to $2.499 billion[217][221] - Pulmonary Hypertension sales grew 12.4% operationally, with UPTRAVI sales increasing 20.7% to $402 million[217][222] - Cardiovascular/Metabolism/Other products declined 8.0% operationally, with XARELTO sales down 9.4% to $625 million[217][222] MedTech Segment Performance - MedTech segment sales increased 10.0% to $22.7 billion, with operational growth of 12.0% and a negative currency impact of 2.0%[225][226] - Interventional Solutions sales surged 46.2% to $4.681 billion, driven by the Abiomed acquisition[226] - Vision sales grew 4.3% to $3.864 billion, with Contact Lenses/Other sales up 4.0% to $2.820 billion[226] - Total MedTech sales increased by 10.0% to $7.458 billion, with operational growth of 10.4% and a currency impact of -0.4%[227] - Interventional Solutions franchise achieved operational sales growth of 48.1%, driven by the acquisition of Abiomed and double-digit growth in Electrophysiology[229] - Orthopaedics franchise saw operational sales growth of 2.6%, with Hips and Knees growing by 6.5% and 6.7% respectively[228] - Vision franchise achieved operational sales growth of 5.4%, with Surgical segment growing by 10.3%[230] Financial Performance and Tax - Consolidated earnings before provision for taxes on income for Q3 2023 was $5.2 billion, representing 24.4% of sales[231] - Cost of products sold increased due to commodity inflation, restructuring-related excess inventory costs, and Abiomed amortization in the MedTech business[232] - Research and Development expenses decreased as a percent to sales, driven by cost management initiatives in the MedTech business and portfolio prioritization in the Innovative Medicine business[235] - Interest income in Q3 2023 was $374 million, up from $150 million in Q3 2022, due to higher rates of interest earned on cash balances[240] - Other (income) expense, net for Q3 2023 was unfavorable by $0.3 billion, primarily due to changes in the fair value of securities[244] - The Company's debt position was $29.9 billion as of October 1, 2023, compared to $32.0 billion the same period a year ago[240] - Innovative Medicine segment income before tax increased to $14.008 billion in the fiscal nine months of 2023, up from $12.424 billion in 2022, representing 34.1% of segment sales compared to 31.5% in 2022[245][247] - MedTech segment income before tax rose to $4.265 billion in the fiscal nine months of 2023, up from $3.641 billion in 2022, accounting for 18.8% of segment sales compared to 17.6% in 2022[245][248] - Worldwide income before tax for the fiscal nine months of 2023 was $10.236 billion, down from $15.519 billion in 2022, primarily due to a $7 billion charge related to the talc settlement proposal and a $0.6 billion unfavorable change in the fair value of the retained stake in Kenvue[245][246] - The worldwide effective income tax rate for the fiscal nine months of 2023 was 10.2%, down from 15.3% in 2022, as the Company continues to evaluate the potential impact of the OECD Pillar Two Framework[254] Cash Flow and Financial Position - Cash and cash equivalents increased to $19.7 billion at the end of the fiscal third quarter of 2023, up from $14.1 billion at the end of fiscal year 2022, driven by $14.9 billion in net cash generated from operating activities[256][257] - The Company secured a new 364-day Credit Facility of $10 billion in September 2023, which expires on September 5, 2024, providing access to substantial sources of funds[261] - As of October 1, 2023, the company had $23.5 billion in cash and equivalents, with a net debt position of $6.4 billion compared to a prior year net cash position of $1.1 billion[266] - The company paid $4.9 billion to the U.S. Treasury in the fiscal nine months of 2023, including $1.5 billion related to foreign undistributed earnings[267] - The company completed a $5.0 billion share repurchase program as of April 2, 2023[267] - The company declared regular cash dividends of $1.19 per share in July and October 2023, payable in September and December respectively[268] Restructuring and Charges - The Company recorded a pre-tax restructuring charge of $0.4 billion in the fiscal nine months of 2023 related to the prioritization of its R&D investment within the Innovative Medicine segment, including the discontinuation of its RSV adult vaccine program[251] - The MedTech segment initiated a restructuring program in the third quarter of 2023, resulting in a pre-tax restructuring expense of $0.2 billion, primarily related to inventory and instrument charges from market and product exits[252] Kenvue IPO and Related Transactions - Kenvue completed its IPO on May 8, 2023, issuing 198,734,444 shares at $22.00 per share, raising net proceeds of $4.2 billion[262] - Johnson & Johnson owned 89.6% of Kenvue's total outstanding shares post-IPO, with a non-controlling interest of $1.3 billion reflected in equity[262] - Johnson & Johnson disposed of 80.1% ownership of Kenvue through an exchange offer, receiving $31.4 billion in common stock and reducing its ownership to 9.5%[264] - Johnson & Johnson recorded a $21.0 billion gain from the Kenvue exchange offer, including a $2.8 billion gain on retained Kenvue shares[265] Subsidiaries and Regional Impact - The company's Russian subsidiaries represented less than 1% of consolidated assets and revenues as of October 1, 2023[270] - The company's Israel subsidiaries represented 1% of consolidated assets and less than 1% of revenues as of October 1, 2023[272] STELARA Biosimilar Settlement - The company anticipates no biosimilar version of STELARA in the U.S. until January 1, 2025, following settlements with third parties[220]

Johnson & Johnson (NYSE:JNJ) Q3 2023 Earnings Conference Call October 17, 2023 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joe Wolk - Executive Vice President, Chief Financial Officer John Reed - Executive Vice President, Pharmaceuticals, R&D Joaquin Duato - Chairman and Chief Executive Officer Erik Haas - Vice President, Litigation Ahmet Tezel - Innovative Medicine and MedTech R&D Conference Call Participants David Risinger - Leerink Partners Matt Miksic - Barclays Ch ...